Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Así es como usted puede verificarlo

Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.

Los sitios web seguros .gov usan HTTPS
Un candado (  ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Pomegranate Juice and Memory

Start: January 2014
End: May 2018
Enrollment: 212

What Is This Study About?

This study will examine whether drinking pomegranate juice daily for 1 year will benefit cognitive abilities in middle-aged and older adults without dementia. Researchers predict that participants who drink pomegranate juice will show better cognitive performance than those who drink a placebo.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 75 Years

Must have:

  • Normal cognition or mild cognitive impairment
  • Adequate seeing and hearing ability to allow neuropsychological testing
  • Screening laboratory tests and EKG without significant abnormalities that might interfere with the study; if tests show abnormalities, subject must obtain written clearance from primary care physician

Must NOT have:

  • Diagnosis of probable Alzheimer's disease or any other dementia
  • Evidence of other neurological or physical illness that can produce cognitive deterioration
  • History of stroke, transient ischemic attack, carotid bruits, or lacunes seen on MRI scan
  • Contraindication to MRI, including claustrophobia, metal in body, surgery within past 60 days, certain implants, or previous abnormal MRI results
  • Evidence of Parkinson's disease
  • History of myocardial infarction within the past year or unstable cardiac disease
  • Uncontrolled hypertension (systolic blood pressure > 170 mm Hg or diastolic blood pressure > 100 mm Hg)
  • History of significant liver disease, clinically significant pulmonary disease, or diabetes
  • Current diagnosis of any major psychiatric disorder
  • Current diagnosis or history of alcoholism or substance addiction
  • Pregnancy
  • Regular use of any medication that may affect cognitive functioning, including: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin
  • Occasional use of anxiety or sleeping medications known to cause cognitive dulling will be allowed but discouraged: chloral hydrate; non-benzodiazepine hypnotics such as Ambien (zolpidem) or Lunesta (eszopiclone); benzodiazepines such as Ativan (lorazepam), Xanax (alprazolam), Klonopin (clonazepam), and Restoril (temazepam)
  • Other prohibited medications: amitriptyline, amiodarone, desipramine, fenofibrate, flecainide, fluconazole, fluoxetine, fluvastatin, fluvoxamine, isoniazid, lovastatin, ondansetron, phenylbutazone, probenecid, sertraline, sulfamethoxazole, sulfaphenazole, teniposide, voriconazole, and zafirlukast; supplements such as ginkgo biloba or anything containing pomegranate or pomegranate juice

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: University of California, Los Angeles

Collaborator Sponsor

  • POM Wonderful LLC

Source: ClinicalTrials.gov ID: NCT02093130

alzheimers.gov/es

Un sitio web oficial del Gobierno de los Estados Unidos, gestionado por el Instituto Nacional sobre el Envejecimiento, parte de los Institutos Nacionales de la Salud